17.9 The Endocrine Pancreas

Pancreatic Islets and Glucose Regulation

The endocrine pancreas is your body's primary blood glucose regulator. While most of the pancreas produces digestive enzymes (its exocrine function), small clusters of endocrine cells scattered throughout the organ secrete hormones that keep blood sugar within a tight range. Understanding how these hormones interact is central to understanding metabolic homeostasis.

Structure of Pancreatic Islets

Pancreatic islets (also called islets of Langerhans) are clusters of endocrine cells that make up only about 1–2% of total pancreatic mass. Despite their small size, they're critical for glucose regulation. Each islet contains several cell types, each secreting a different hormone:

• Alpha cells (α cells) make up 15–20% of islet cells. They secrete glucagon, which raises blood glucose by stimulating glycogenolysis (glycogen breakdown) and gluconeogenesis (new glucose production) in the liver.
• Beta cells (β cells) are the most abundant islet cell type (65–80%). When blood glucose rises, beta cells release insulin, which promotes glucose uptake and storage, bringing blood glucose back down. Beta cells also produce amylin, a hormone that slows gastric emptying and promotes satiety, helping to prevent post-meal glucose spikes.
• Delta cells (δ cells) account for 3–10% of islet cells. They secrete somatostatin, which acts as a local brake on both insulin and glucagon secretion.
• PP cells (F cells) make up roughly 1% of islet cells. They secrete pancreatic polypeptide, which regulates both exocrine and endocrine pancreatic secretion.

Insulin and Glucagon in Glucose Regulation

Insulin and glucagon are antagonistic hormones that work as a pair to maintain blood glucose homeostasis. Think of them as a push-pull system: insulin pushes glucose out of the blood and into cells, while glucagon pulls glucose back into the blood from storage.

Insulin lowers blood glucose by:

1. Stimulating glucose uptake in skeletal muscle and adipose tissue via GLUT4 glucose transporters that move to the cell surface
2. Promoting glycogenesis (glucose → glycogen) in the liver and skeletal muscle
3. Inhibiting gluconeogenesis and glycogenolysis in the liver
4. Enhancing lipogenesis (fat synthesis) and protein synthesis

Glucagon raises blood glucose by:

1. Stimulating glycogenolysis in the liver, releasing stored glucose into the bloodstream
2. Promoting gluconeogenesis in the liver, producing new glucose from non-carbohydrate sources like amino acids and glycerol from lipids
3. Enhancing lipolysis in adipose tissue, which provides energy substrates (particularly glycerol) that fuel gluconeogenesis

The insulin-to-glucagon ratio determines the net metabolic effect at any given time. After a meal, this ratio is high, favoring glucose storage and utilization. During fasting, the ratio drops, favoring glucose production and release to keep the brain and other tissues fueled.

Effects of Other Pancreatic Hormones

Somatostatin has broad inhibitory effects beyond the pancreas:

• Inhibits secretion of both insulin and glucagon from neighboring islet cells
• Suppresses release of growth hormone (GH) and thyroid-stimulating hormone (TSH) from the anterior pituitary
• Reduces secretion of gastrointestinal hormones like gastrin, cholecystokinin (CCK), and secretin, which decreases GI motility and slows nutrient absorption

Pancreatic polypeptide (PP) primarily affects digestive function:

• Inhibits pancreatic exocrine secretion of digestive enzymes
• Reduces gallbladder contraction and bile secretion
• Slows gastric emptying and intestinal motility
• Suppresses appetite by acting on the hypothalamus
• May modulate insulin and glucagon secretion, though its exact role here is not fully understood

Incretin Hormones and Glucose Regulation

Not all glucose regulation originates in the pancreas itself. Incretin hormones are released by intestinal cells in response to food intake and amplify the insulin response to a meal. The two main incretins are:

• Glucose-dependent insulinotropic polypeptide (GIP), released from the duodenum
• Glucagon-like peptide-1 (GLP-1), released from the ileum and colon

These hormones enhance insulin secretion only when blood glucose is elevated, which is why they're called "glucose-dependent." They also inhibit glucagon secretion, slow gastric emptying, and promote satiety. This is clinically relevant because GLP-1 receptor agonists are now widely used to treat Type 2 diabetes.

Diabetes Mellitus

Diabetes mellitus results from disrupted insulin signaling and comes in two major forms:

• Type 1 diabetes is an autoimmune disorder in which the immune system destroys pancreatic beta cells. This leads to absolute insulin deficiency, meaning patients require exogenous insulin to survive. It typically presents in childhood or adolescence.
• Type 2 diabetes is characterized by insulin resistance (cells respond poorly to insulin) and often a progressive decline in insulin production. It's strongly associated with obesity, physical inactivity, and genetic predisposition. Type 2 accounts for roughly 90–95% of all diabetes cases.

In both types, the result is chronic hyperglycemia (elevated blood glucose), which over time can damage blood vessels, nerves, kidneys, and the eyes.